Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors
Contact:
NCT Number:
Protocol:
AAAU8909
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I
The purpose of this study is to test a combination of 2 new drugs called RMC-6291 and RMC 6236 (the study drugs). RMC-6291 and RMC-6236 are new investigational (ie, experimental) drugs, which means that they are not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC 6291 and RMC-6236 will be tested together in humans. This study will test the safety and anti-tumor effects of RMC-6291 and RMC-6236 when given together at different doses in participants with a change or alteration in the KRASG12C gene within the cells that make up their tumor. How a participant's body processes RMC-6291 and RMC-6236 when they are given together will also be tested.
Are you Eligible? (Inclusion Criteria)
- You are ≥ 18 years of age, able and willing at the time of signing the informed consent form. 2. Participant must have a life expectancy of at least 3 months, in the opinion of the Investigator 3. You are able to take oral medications
Specialty Area(s)
Bladder Cancer , Breast Cancer, Colon and Rectal Cancer, Esophageal Cancer, Gynecologic Cancers, Cervical Cancer, Ovarian Cancer, Uterine (Endometrial) Cancer, Head and Neck/Oral Cancers, Kidney Cancer/Adrenal Cancer, Liver Cancer, Skin cancers, Melanoma, Pancreatic Cancer, Prostate Cancer, Stomach Cancer, Testicular Cancer, Thyroid Cancer
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
